



ZIOPHARM Oncology, Inc.  
 Investor Relations Department  
 One First Ave., Parris Building, # 34  
 Navy Yard Plaza  
 Boston, MA 02199  
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: ZIOP**

Last Trade:	6.23
Trade Time:	4:15 PM ET Jun 23, 2017
Change:	0.16 (+2.636%)
Day Range	5.99 - 6.34
52-Week Range	4.45 - 7.88
Volume	1,824,642


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jun 5, 2017  
[ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting](#)
- Jun 2, 2017  
[ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 17, 2017  
[ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Velelimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting](#)
- May 12, 2017  
[ZIOPHARM Oncology Announces Pricing of \\$50 Million Follow-On Offering of Common Stock](#)
- May 2, 2017  
[ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia](#)

**Financials** [\[ View all \]](#)

- Feb 16, 2017  
[Annual Report \(10-K\)](#)
- Apr 28, 2017  
[Proxy Statement \(DEF 14A\)](#)
- May 1, 2017  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016  
[Quarterly Report \(10-Q\)](#)